PROK — ProKidney Corp.
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 204
- Website: https://www.prokidney.com
Latest SEC filings for PROK
- SCHEDULE 13G/A — 2026-08-12
- 10-Q — 2026-08-10
- 8-K — 2026-08-10
- 8-K — 2026-05-29
- 8-K — 2026-05-15
- 10-Q — 2026-05-15
- SCHEDULE 13D/A — 2026-04-30
- 10-K — 2026-03-18
- 8-K — 2026-03-18
- SCHEDULE 13G — 2026-02-12
Latest PROK news
- — ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026 (GlobeNewswire Inc.)
Educational tool only — not investment advice.